23 November 2015 - In final draft guidance as part of its Highly Specialised Technologies Programme, NICE has provisionally recommended Elosulfase alfa (Vimizin, BioMarin) for the treatment of a very rare inherited lysosomal storage disease when used as part of a managed access agreement.

For more details, go to: http://www.nice.org.uk/News/Press-and-Media/nice-draft-guidance-recommends-elosulfase-alfa-vimizim-for-treatment-of-very-rare-life-limiting-genetic-disorder-under-managed-access-agreement